Brought to you by Portland Press Ltd.
Published on behalf of the International Federation for Cell Biology
Cancer Cell death Cell cycle Cytoskeleton Exo/endocytosis Differentiation Division Organelles Signalling Stem cells Trafficking
Cell Biology International (2012) 36, 441–447 (Printed in Great Britain)
1α,25-dihydroxyvitamin D3 enhances fast-myosin heavy chain expression in differentiated C2C12 myoblasts
Hiroshi Okuno, Koshi N. Kishimoto1, Masahito Hatori and Eiji Itoi
Department of Orthopaedic Surgery, Tohoku University Graduate School of Medicine, Sendai, Japan


We investigated the effect of VD3 (1α,25-dihydroxyvitamin D3) on the proliferating, differentiating and differentiated phases of C2C12 myoblasts, a mouse skeletal muscle cell line. VD3 treatment in 10% FBS (fetal bovine serum) inhibited the proliferation and viability of the cells in a dose-dependent manner. It also dose-dependently increased the percentage of cells in the G0/G1 phase as shown by flow cytometry. In the differentiating phase, VD3 treatment inhibited the formation of myotubes and the expression of total myosin heavy chain at both the mRNA and protein levels. In the differentiated phase, treatment had no significant effect on the amount of total myosin heavy chain, as Western blot analysis with MF20 antibody [DSHB (Developmental Studies Hybridoma Bank)] showed. However, significantly greater expression of fast myosin heavy chain in 1 nM VD3 was found by Western blot analysis with MY-32 (Sigma). Thus VD3 inhibited the proliferation of myoblasts during proliferating and differentiating phases, whereas it increased the expression of the fast myosin heavy chain isoform in the differentiated phase. The data indicate that an adequate concentration of VD3 might have an anabolic effect on differentiated skeletal muscle.


Key words: C2C12, differentiation, myosin heavy chain, proliferation, skeletal muscle, vitamin D

Abbreviations: BCA, bicinchoninic acid, CDK, cyclin-dependent kinase, CKI, CDK inhibitor, CT, threshold cycle value, DMEM, Dulbecco's modified Eagle's medium, FBS, fetal bovine serum, GAPDH, glyceraldhyde-3-phosphate dehydrogenase, HS, horse serum, RT–PCR, reverse transcription–PCR, VD3, 1α,25-dihydroxyvitamin D3, VDR, vitamin D receptor

1To whom correspondence should be addressed (email kishimoto@med.tohoku.ac.jp).


1. Introduction

Vitamin D plays a major role in the regulation of calcium homoeostasis. The active form of vitamin D [VD3 (1α,25-dihydroxyvitamin D3)] is widely used in the treatment of metabolic bone diseases, such as rickets/osteomalacia, renal osteodystrophy and osteoporosis. Treatment with hydroxylated vitamin D treatment increases bone density (Papadimitropoulos et al., 2002) mainly through increased calcium uptake in the intestine (Kumar, 1986). In addition to its classical function in calcium metabolism, VD3 or its analogues regulate cell proliferation and differentiation (Miyaura et al., 1981; Walters, 1992). It has been used in the treatment of psoriasis, characterized by hyperproliferation of epidermal keratinocytes.

VD3 acts through binding in target cells to the VDR (vitamin D receptor) that belongs to the nuclear super family. VDR is expressed in various tissues including kidney, intestine, bone, parathyroid glands and skin (Minghetti and Norman, 1988; Walters, 1992; Haussler et al., 1998). Since myoblasts and myotubes have also been shown to contain VDRs in chicks (Boland et al., 1985), mice (Simpson et al., 1985) and human (Costa et al., 1986), muscle cells could respond to VD3 through VDR.

The effects of VD3 have been examined in many types of cells in different phases of differentiation. It inhibits DNA and protein synthesis dose-dependently in human myoblasts and myotubes (Costa et al., 1986). VD3 treatment in early stages of culture increases DNA synthesis and cell growth of chick embryo myoblasts in the proliferating phase in high serum. However, VD3 treatment during the subsequent stage of chick myoblast differentiation in low serum inhibits DNA synthesis (Drittanti et al., 1989). The effects of VD3 may vary with the type of cell and stage of differentiation when treatment is given.

C2C12 is a murine myogenic cell line that proliferate rapidly, and when confluent and in the presence of 2% HS (horse serum), they begin to fuse and differentiate into myotubes. When VD3 treatment began at the change to the differentiation medium, down-regulation of myosin heavy chain isoforms and myogenic transcription factors (e.g. Myf5 and myogenin) occurred (Endo et al., 2003). However, the effect of VD3 on differentiated C2C12 cells has not been investigated, which might best be done with differentiated myocytes that reflect the clinical situation.

To analyse the effect of VD3 on myoblasts and myotubes, VD3 was added in three phases of C2C12 myoblasts differentiation, proliferating, differentiating and differentiated, and cells were analysed by cell counting, colorimetry and flow cytometry. Differentiation was also examined by quantitative RT–PCR (reverse transcription–PCR), immunocytofluorescence and Western blotting for myosin heavy chain and its isoforms.

2. Materials and methods

2.1. Cell culture

C2C12, a mouse myoblast cell line obtained from Riken cell bank (Tsukuba) was maintained for growth in DMEM (Dulbecco's modified Eagle's medium: Invitrogen) supplemented with 10% FBS (fetal bovine serum) and 1% penicillin/streptomycin (Invitrogen) at 37°C in a 5% CO2 in air humidified chamber. The cells were plated at 1×105 cells per well in 6-well plates and incubated for 3 days (proliferating phase). As the cells approached confluency, the growth medium was replaced with a DMEM supplemented with 2% HS (Invitrogen) and 1% penicillin/streptomycin to initiate differentiation. The medium was changed every other day, and VD3 was added at 0, 1, 10 or 100 nM in ethanol. VD3 treatment commenced in the differentiating phase when the medium was changed to HS. VD3 treatment commenced in the fully differentiated phase was defined as from 8 days culture in HS (Figure 1A).

2.2. Cell proliferation assay

Proliferation of C2C12 myoblasts was measured by both conventional haemocytometer cell counting and the WST-1 proliferation assay (Dojindo). Cells were grown for 72 h before analysis. Six-well plates with 5×104 cells per well were used for cell counting, and 96-well plates with 5×103 cells per well were used for the WST-1 assay. WST-1 solution was added to the 96-well plates for analysis by optical densitometry after 2 h incubation.

2.3. Cell cycle analysis

To analyse the cell cycle distribution of C2C12 cells in the proliferating phase, the cells were cultured with or without VD3. After 72 h, the cells were harvested and fixed with 70% ethanol. The cells were kept at −20°C until staining. Fixed cells were treated with RNase A (Sigma) in PBS for 30 min, followed by staining with 50 mg/l propidium iodide (Sigma) in PBS. Flow cytometry was carried out with a BD FACS Calibur (Becton Dickinson). Data acquisition and analysis relied on CellQuest Pro (BD) software.

2.4. Total RNA extraction and quantitative RT–PCR

Total RNA was isolated from cell cultures using RNeasy Mini Kit (Qiagen). RT was performed using a High Capacity cDNA RT kit (Applied Biosystems). Quantitative real-time PCR assay was done with Power SYBER Green PCR Master Mix (Applied Biosystems) on the ABI PRISM 7700 Sequence Detection System (Applied Biosystems) to assess the expression of p21, p27, myogenin, myosin heavy chain neonatal, myosin heavy chain isoforms and VDR routinely in duplicate or triplicate. Each primer was designed from the GenBank® database as follows: p21, p27, myogenin, myosin heavy chain neonatal, myosin heavy chain I/β, myosin heavy chain IIa, myosin heavy chain IId/x, myosin heavy chain IIb and VDR (Table 1). The fractional cycle number at which the fluorescence passes the fixed CT (threshold cycle values) was used for quantifying by the comparative CT method. Sample values were normalized to the threshold value for GAPDH (glyceraldhyde-3-phosphate dehydrogenase) for each time-point: ΔCT = CT (experiments)−CT (GAPDH). The CT value for vehicle was used as a reference. ΔΔCT = ΔCT (VD3)−ΔCT (vehicle). The fold change in mRNA expression for each time-point was plotted using the vehicle as a reference: 2−ΔΔCT(vehicle) = 1.


Table 1 List of PCR primers used in this study

Gene Primer Accession number
p21 F: 5′-GAGAAGGGCACCAAGCAG-3′ AF035683
R: 5′-AGTCTTAGTTTTCACCACGACCTT-3′
p27 F: 5′-GAGCAGTGTCCAGGGATGAG-3′ U09968
R : 5'-TCTGTTCTGTTGGCCCTTTT-3'
VDR F: 5′-CACCTGGCTGATCTTGTCAGT-3′ NM_009504
R: 5′-CTGGTCATCAGAGGTGAGGTC-3′
myogenin F: 5′-CCTTGCTCAGCTCCCTCA-3′ NM_031189
R: 5′-TGGGAGTTGCATTCACTGG-3′
Myosin heavy chain neonatal F: 5′-GGCGAAGGTGAAATCCTACA-3′ NM_177369
R: 5′-GTTGGCATTGGATTGTTCCT-3′
Myosin heavy chain I/β F: 5′-CGCATCAAGGAGCTCACC-3′ NM_080728
R: 5′-CTGCAGCCGCAGTAGGTT-3′
Myosin heavy chain IIa F: 5′-AAATCTTACAAGAGACAAGCTGAGG-3′ NM_001039545
R: 5′-TGCGGAACTTGGATAGATTTG-3′
Myosin heavy chain IId/x F: 5′-AATCAAAGGTCAAGGCCTACAA-3′ NM_030679
R: 5′-GAATTTGGCCAGGTTGACAT-3′
Myosin heavy chain IIb F: 5′-TGGCCGAGCAAGAGCTAC-3′ NM_010855
R: 5′-TTGATGAGGCTGGTGTTCTG-3′


F, Forward; R, Reverse.



2.5. Immunocytofluorescence

Cultured C2C12 cells were fixed in −20°C ethanol for 10 min, and permeated with PBS containing 0.1% Tween 20 (ICN Biomedicals) for 15 min at room temperature. Cells were incubated with a primary mouse monoclonal sarcomeric myosin-specific MF20 antibody [DSHB (Developmental Studies Hybridoma Bank) IA] in the PBS at 4°C overnight, followed by incubation with Alexa Fluor® 555-conjugated goat anti-mouse IgG secondary antibody (Invitrogen) in the PBS for 2 h at room temperature. Nuclei were stained with Hoechst 33342 (1:1000; Sigma).

2.6. Western blot analysis

C2C12 cells were washed with PBS and lysed in 200 μl of lysis buffer (40 mM Tris/HCl, pH 7.5, 300 mM KCl, 1% Triton X-100 and 2 mM EDTA) mixed with protease inhibitor cocktail (1:50; Sigma) for 40 min on ice. The extracts were cleared by centrifugation at 15000 g for 30 min. Protein concentration was measured by the BCA (bicinchoninic acid) assay using a Pierce Microplate BCA Protein Assay Kit (Thermo). Equal amounts of protein in the supernatant (15 mg protein/lane) were electrophoresed on 8% SDS gels and blotted to PVDF membranes (Bio-Rad). The membranes were blocked with TBST buffer (0.01 M Tris/HCl, pH 7.5, 0.15 M NaCl and 0.05% Tween 20) containing non-fat dried skimmed milk powder for 1 h at room temperature and incubated in TBST buffer at 4°C overnight with either anti- myosin heavy chain fast (MY32) mAb (1:1000; Sigma), anti-GAPDH (6C5) mAb (1:1000; Santa Cruz) or MF20 hybridoma supernatant before being incubated with HRP (horseradish peroxidase)-conjugated secondary anti-mouse IgG (1:2500; Invitrogen) in TBST for 1 h at room temperature. Signals were visualized by chemiluminescence using an ECL® Western Blotting Detection Reagents (GE Healthcare) with a digital luminescent image analyser LAS-1000 (Fujifilm). The band intensity was analysed by ImageJ 1.37v software program (National Institutes of Health) and normalized by GAPDH.

2.7. Statistical analysis

Statistical significance between the vehicle-treated and the VD3-treated cells was judged by Welch's t test. All data were expressed as the means±S.D., with P<0.05 being considered as significant. A difference of <2-fold in the amount of the mRNA level was not considered to be significant, even when it was statistically significant.

3. Results

3.1. Effects of VD3 on C2C12 myoblasts in the proliferating phase

VD3 (at 1, 10 or 100 nM) inhibited the proliferation of C2C12 myoblasts in a dose-dependent manner over 72 h. The inhibitory effects were significant at 1 nM (Figures 2A and 2B). At 72 h, cell cycle analysis showed a dose-dependent increase in the percentage of cells in G0/G1 phases (Figure 2C). Quantitative RT–PCR for VDR increased in a dose-dependent manner (Figure 2D). p21 and p27 gene expression were elevated (Figures 2E and 2F).

3.2. The effects of VD3 on C2C12 myoblasts in the differentiating phase

In the differentiating phase of C2C12 myoblasts, VD3 treatment significantly decreased mRNA expression of neonatal myosin heavy chain. At 1 and 10 nM, VD3 tended to decrease the mRNA level of myogenin, which was significantly the case at 100 nM (Figure 3A). Immunocytofluorescence for myosin heavy chain was decreased in myosin heavy chain-positive myocytes relative to the VD3 concentration (Figure 3B). Western blotting also showed that myosin heavy chain protein decreased significantly in a dose-dependent manner (Figure 3C).

3.3. Effects of VD3 on C2C12 in the differentiated phase

Myosin heavy chain isoforms were investigated at the mRNA level to follow the natural course of their expression. Differentiation of C2C12 myoblasts increased for 8 days before reaching a plateau (Figure 1B). VD3 commencing in the differentiated phase did not significantly affect neonatal myosin heavy chain at the mRNA level (Figure 4A). Myosin heavy chain-positive cells decreased in 100 nM VD3, but this was less prominent than in the differentiating phase. Myosin heavy chain-positive cells were short and round after 100-nM VD3 treatment (Figure 4B). One and 10 nM VD3 tended to increase the protein level of myosin heavy chain, but not significantly, although it did at 100 nM (Figure 4C). Myosin heavy chain type IIa mRNA level was significantly increased by 1 nM VD3, as also the myosin heavy chain type IId/x mRNA level (Figure 5A). Western blotting analysis showed that fast myosin heavy chain isoform had increased expression in 1 and 10 nM VD3, which was significant at the lower concentration (Figure 5B).

4. Discussion

The steroid hormone, VD3 inhibits the proliferation in the proliferating phase of C2C12 myoblasts and the expression of myosin heavy chain in the differentiating phase. In the differentiated phase, 1 nM VD3 tended to increase the expression of myosin heavy chain and significantly enhanced the fast myosin heavy chain isoform, which is the first demonstration to confirm the anabolic effect of the steroid on mouse skeletal muscle cell in vitro, thus indicating some of the clinical effects as previously reported.

Previous in vitro studies with squamous cell carcinoma (Hershberger et al., 1999), prostate adenocarcinoma (Getzenberg et al., 1997), cancers of the ovary (Zhang et al., 2005), breast (Colston et al., 1992) and lung (Nakagawa et al., 2005) showed that the addition of VD3 or its analogues had significant anticancer effects, and cell cycle perturbation has been analysed as an anti-proliferative activity of VD3 in tumour cells. These effects are mediated through the VDR and this regulates proliferation, apoptosis (Simboli-Campbell et al., 1996) and angiogenesis (Mantell et al., 2000). The dose-dependent increase of the VDR mRNA level we have shown suggests that VD3 induced cell-cycle arrest through VDR in proliferating phase C2C12 cells.

Cell cycle progression is regulated by cyclins, and their association with CDKs (cyclin-dependent kinases) and CKIs (CDK inhibitors). In particular, p21 (Harper et al., 1993) and p27 (Polyak et al., 1994; Toyoshima and Hunter, 1994) are inhibitors of G1 CDK. Expressions of p21 and p27 seem to be increased by VD3 treatment inducing a G0/G1 phase arrest in squamous cell carcinoma cell lines (Hager et al., 2001) and breast cancer MCF-7 cells (Verlinden et al., 1998). We found that gene expression of p21 and p27 was up-regulated by VD3 treatment in C2C12 cells (Figures 2E and 2F). G0/G1 arrest of proliferating C2C12 might be influenced by CDKs–CKIs through p21 and p27, as in other cell lines.

Gene expression of myosin heavy chain isoforms reached a plateau before 8 days of differentiation (Figure 1B), but a longer period of culture might make further differentiation into mature myotubes possible. However, prolonged culture could also result in the detachment of cells from the culture dishes by myotube contraction. Starting VD3 treatment from 8 days after differentiation seemed to prevent cell detachment.

Gene expression of neonatal myosin heavy chain in the differentiated phase was not significantly decreased by VD3 treatment, unlike in the differentiating phase. The differentiated phase contains more differentiated myotubes and fewer myoblasts than the other phases. This may more closely mimic real muscle tissue. The smaller proportion of myoblasts in the differentiated phase could be the reason for no inhibitory effect on cell proliferation being seen in this phase.

VD3 acts through two different mechanisms (Walters, 1992). VDR is widely expressed in the various tissues such as skin, parathyroid, kidney, intestine and bone (Haussler et al., 1998). It is expressed from myoblasts to myotubes in cloned human skeletal muscle cells (Costa et al., 1986). VD3 has some effects on transcription of the target gene via VDR as a nuclear receptor (Haussler et al., 1998), effects considered as genomic actions. Another is a non-genomic mechanism as VD3 exerts fast effects on calcium metabolism in muscle cell through stimulation of voltage-dependent Ca2+ channels, which is mediated by the cAMP messenger system (De Boland and Boland, 1994). VD3 can activate p38 MAPK (mitogen-activated protein kinase) and ERK1/2 (extracellular-signal-regulated kinase 1/2) in C2C12 (Buitrago et al., 2006; Ronda et al., 2007).

Yoshizawa et al. (1997) have generated VDR gene-deleted mice (VDR−/−) as an animal model of type II vitamin D-dependent rickets. These mice have a unique feature in growing normally with no bone or metabolic anomalies for 3 weeks from birth until they are weaned. This feature is presumably due to the high calcium content or other critical nutrients in the breast milk. Further analysis showed that the diameters of skeletal muscle fibre at 3 weeks old were significantly decreased (∼20%) on average compared with wild-type mice (Endo et al., 2003). Our in vitro results may be more consistent with the muscle phenotype of the wild-type mice than the VDR−/− mice. Moreover, skeletal muscle may be a direct physiological target of VDR actions.

Skeletal muscle fibres are classified as slow-twitch (type I) and fast-twitch (type II) fibres on the basis of the contractile properties and oxidative capacity. Fast-twitch (type II) fibres have 4 subtypes (IIA, IIB, IIC and IID/X). They are classified on the basis of myosin heavy chain isoforms into types I, IIa, IId/x and IIb by histochemical and immunohistochemical staining of myosin heavy chain (Billeter et al., 1981; Staron and Pette, 1986; Termin et al., 1989; Schiaffino and Reggiani, 1996).

Many studies suggest that the expression of myosin heavy chain or myosin heavy chain subtypes, which we used as differentiation markers, is regulated by multiple signalling pathways and transcription factors rather than by a single signalling pathway (Spangenburg and Booth, 2003). In this and previous studies, we found that VD3 plays an important role in cell proliferation and differentiation in C2C12. VD3 treatment enhanced fast myosin heavy chain expression in the differentiated C2C12 cells (Figure 5B). However, the molecular mechanisms of the VD3 action on fast myosin heavy chain synthesis remain unexplained.

Analysis of cells from VDR−/− or 1α-hydroxylase−/− mice may be useful for clarification of the VD3 mechanisms. Alternatively, knock-down of up-regulated genes by VD3 in skeletal muscle cells could provide important information about the relationship between VD3 treatment and the expression of fast myosin heavy chain.

We have shown that 100 nM VD3 inhibited cell proliferation in the proliferating phase, decreased myosin heavy chain synthesis and the deformed cell shapes in the differentiating and differentiated phases, which might be due to some toxic effects of VD3.

A recent meta-analysis (Bischoff-Ferrari et al., 2004) based on several randomized clinical trials (Graafmans et al., 1996; Pfeifer et al., 2000; Gallagher et al., 2001; Bischoff et al., 2003; Dukas et al., 2004) found that vitamin D supplementation reduced the risk of falls. The mechanisms by which vitamin D reduces this risk have not been clarified. Clinically, it is known that vitamin D supplementation improves muscle strength in patients with vitamin D deficiency (Eastwood et al., 1977). The effect of vitamin D in reducing falls may be due to increasing muscle strength by its direct effects on muscle tissue. Fast-twitch (type II) muscle has the features of fast contraction and easy fatigability. Increase of fast-twitch (type II) muscle fibre may contribute in maintaining physical balance in momentary postural change, reducing falls. Vitamin D treatment accounted for a 59% reduction in falls, increased the relative number and size of type II muscle fibres, and improved muscle strength compared with placebo (Sato et al., 2005). Our study suggests that the elevated expression of fast myosin heavy chain may explain how vitamin D supplementation results in these clinical responses, although there could be many other factors that contribute.

Author contribution

Hiroshi Okuno and Koshi Kishimoto conceived the experiments. Hiroshi Okuno performed the experiments, and analysed data together with Koshi Kishimoto. Hiroshi Okuno and Koshi Kishimoto co-wrote the paper. Masahito Hatori and Eiji Itoi provided valuable help on the preparing the manuscript. All authors discussed the results and commented on the paper.

AcknowledgementsFunding

We thank Mr Katsuyoshi Shoji and Ms Michiko Fukuyama for the technical assistance.

Funding

This work was supported by the Ministry of Health, Labour and Welfare in Japan [grant number H18 Tyoju-Ippan 031].

REFERENCES

Billeter, R, Heizmann, CW and Howald HJenny, E (1981) Analysis of myosin light and heavy chain types in single human skeletal muscle fibers. Eur J Biochem 116, 389-95
Crossref   Medline   1st Citation  

Bischoff-Ferrari, HA, Dawson-Hughes, B, Willett, WC, Staehelin, HB, Bazemore, MG and Zee, RY (2004) Effect of vitamin D on falls: a meta-analysis. JAMA, J Am Med Assoc 291, 1999-2006
Crossref   1st Citation  

Bischoff, HA, Stahelin, HB, Dick, W, Akos, R, Knecht, M and Salis, C (2003) Effects of vitamin D and calcium supplementation on falls: a randomized controlled trial. J Bone Miner Res 18, 343-51
Crossref   Medline   1st Citation  

Boland, R, Norman, A and Ritz EHasselbach, W (1985) Presence of a 1,25-dihydroxy-vitamin D3 receptor in chick skeletal muscle myoblasts. Biochem Biophys Res Commun 128, 305-11
Crossref   Medline   1st Citation  

Buitrago, CG, Ronda, AC, de Boland, AR and Boland, R (2006) Map Kinases P38 and Jnk are activated by the steroid hormone 1alpha,25(Oh)2-vitamin D3 in the C2C12 muscle cell line. J Cell Biochem 97, 698-708
Crossref   Medline   1st Citation  

Colston, KW, Chander, SK, Mackay, AG and Coombes, RC (1992) Effects of synthetic vitamin D analogues on breast cancer cell proliferation in vivo and in vitro. Biochem Pharmacol 44, 693-702
Crossref   Medline   1st Citation  

Costa, EM, Blau, HM and Feldman, D (1986) 1,25-Dihydroxyvitamin D3 receptors and hormonal responses in cloned human skeletal muscle cells. Endocrinology 119, 2214-20
Crossref   Medline   1st Citation   2nd   3rd  

De Boland, AR and Boland, RL (1994) Non-genomic signal transduction pathway of vitamin D in muscle. Cell Signal 6, 717-24
Crossref   Medline   1st Citation  

Drittanti, L, de Boland, AR and Boland, R (1989) Modulation of DNA synthesis in cultured muscle cells by 1,25-dihydroxyvitamin D-3. Biochim Biophys Acta 1014, 112-9
Crossref   Medline   1st Citation  

Dukas, L, Bischoff, HA, Lindpaintner, LS, Schacht, E, Birkner-Binder, D and Damm, TN (2004) Alfacalcidol reduces the number of fallers in a community-dwelling elderly population with a minimum calcium intake of more than 500 Mg daily. J Am Geriatr Soc 52, 230-6
Crossref   Medline   1st Citation  

Eastwood, JB, Stamp, TC, De Wardener, HE and Bordier PJArnaud, CD (1977) The effect of 25-hydroxy vitamin D3 in the osteomalacia of chronic renal failure. Clin Sci Mol Med 52, 499-508
Medline   1st Citation  

Endo, I, Inoue, D, Mitsui, T, Umaki, Y, Akaike, M and Yoshizawa, T (2003) Deletion of vitamin D receptor gene in mice results in abnormal skeletal muscle development with deregulated expression of myoregulatory transcription factors. Endocrinology 144, 5138-44
Crossref   Medline   1st Citation   2nd  

Gallagher, JC, Fowler, SE, Detter, JR and Sherman, SS (2001) Combination treatment with estrogen and calcitriol in the prevention of age-related bone loss. J Clin Endocrinol Metab 86, 3618-28
Crossref   Medline   1st Citation  

Getzenberg, RH, Light, BW, Lapco, PE, Konety, BR, Nangia, AK and Acierno, JS (1997) Vitamin D inhibition of prostate adenocarcinoma growth and metastasis in the dunning rat prostate model system. Urology 50, 999-1006
Crossref   Medline   1st Citation  

Graafmans, WC, Ooms, ME, Hofstee, HM, Bezemer, PD, Bouter, LM and Lips, P (1996) Falls in the elderly: a prospective study of risk factors and risk profiles. Am J Epidemiol 143, 1129-36
Medline   1st Citation  

Hager, G, Formanek, M, Gedlicka, C, Thurnher, D and Knerer BKornfehl, J (2001) 1,25(Oh)2 vitamin D3 induces elevated expression of the cell cycle-regulating genes P21 and P27 in squamous carcinoma cell lines of the head and neck. Acta Otolaryngol 121, 103-9
Crossref   Medline   1st Citation  

Harper, JW, Adami, GR, Wei, N, Keyomarsi, K and Elledge, SJ (1993) The P21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75, 805-16
Crossref   Medline   1st Citation  

Haussler, MR, Whitfield, GK, Haussler, CA, Hsieh, JC, Thompson, PD and Selznick, SH (1998) The nuclear vitamin D receptor: biological and molecular regulatory properties revealed. J Bone Miner Res 13, 325-49
Crossref   Medline   1st Citation   2nd   3rd  

Hershberger, PA, Modzelewski, RA, Shurin, ZR, Rueger, RM, Trump, DL and Johnson, CS (1999) 1,25-Dihydroxycholecalciferol (1,25-D3) inhibits the growth of squamous cell carcinoma and down-modulates P21(Waf1/Cip1) in vitro and in vivo. Cancer Res 59, 2644-9
Medline   1st Citation  

Kumar, R (1986) The Metabolism and mechanism of action of 1,25-dihydroxyvitamin D3. Kidney Int 30, 793-803
Crossref   Medline   1st Citation  

Mantell, DJ, Owens, PE, Bundred, NJ, Mawer, EB and Canfield, AE (2000) 1 Alpha,25-dihydroxyvitamin D(3) inhibits angiogenesis in vitro and in vivo. Circ Res 87, 214-20
Medline   1st Citation  

Minghetti, PP and Norman, AW (1988) 1,25(Oh)2-vitamin D3 receptors: gene regulation and genetic circuitry. FASEB J 2, 3043-53
Medline   1st Citation  

Miyaura, C, Abe, E, Kuribayashi, T, Tanaka, H, Konno, K and Nishii, Y (1981) 1 Alpha,25-dihydroxyvitamin D3 induces differentiation of human myeloid leukemia cells. Biochem Biophys Res Commun 102, 937-43
Crossref   Medline   1st Citation  

Nakagawa, K, Kawaura, A, Kato, S, Takeda, E and Okano, T (2005) 1 alpha,25-dihydroxyvitamin D(3) is a preventive factor in the metastasis of lung cancer. Carcinogenesis 26, 429-40
Medline   1st Citation  

Papadimitropoulos, E, Wells, G, Shea, B, Gillespie, W, Weaver, B and Zytaruk, N (2002) Meta-analyses of therapies for postmenopausal osteoporosis. VIII: meta-analysis of the efficacy of vitamin D treatment in preventing osteoporosis in postmenopausal women. Endocr rev 23, 560-9
Crossref   Medline   1st Citation  

Pfeifer, M, Begerow, B, Minne, HW, Abrams, C and Nachtigall DHansen, C (2000) Effects of a short-term vitamin D and calcium supplementation on body sway and secondary hyperparathyroidism in elderly women. J Bone Miner Res 15, 1113-8
Crossref   Medline   1st Citation  

Polyak, K, Kato, JY, Solomon, MJ, Sherr, CJ, Massague, J and Roberts, JM (1994) P27Kip1, a Cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest. Genes Dev 8, 9-22
Crossref   Medline   1st Citation  

Ronda, AC, Buitrago, C, Colicheo, A, de Boland, AR and Roldan EBoland, R (2007) Activation of mapks by 1alpha,25(Oh)2-vitamin D3 and 17beta-estradiol in skeletal muscle cells leads to phosphorylation of elk-1 and creb transcription factors. J Steroid Biochem Mol Biol 103, 462-6
Crossref   Medline   1st Citation  

Sato, Y, Iwamoto, J and Kanoko TSatoh, K (2005) Low-dose vitamin D prevents muscular atrophy and reduces falls and hip fractures in women after stroke: a randomized controlled trial. Cerebrovasc Dis 20, 187-92
Crossref   Medline   1st Citation  

Schiaffino, S and Reggiani, C (1996) Molecular diversity of myofibrillar proteins: gene regulation and functional significance. Physiol Rev 76, 371-23
Medline   1st Citation  

Simboli-Campbell, M, Narvaez, CJ, Tenniswood, M and Welsh, J (1996) 1,25-dihydroxyvitamin D3 induces morphological and biochemical markers of apoptosis in Mcf-7 breast cancer cells. J Steroid Biochem Mol Biol 58, 367-76
Crossref   Medline   1st Citation  

Simpson, RU, Thomas, GA and Arnold, AJ (1985) Identification of 1,25-dihydroxyvitamin D3 receptors and activities in muscle. J Biol Chem 260, 8882-91
Medline   1st Citation  

Spangenburg, EE and Booth, FW (2003) Molecular regulation of individual skeletal muscle fibre types. Acta Physiol Scand 178, 413-24
Crossref   Medline   1st Citation  

Staron, RS and Pette, D (1986) Correlation between myofibrillar atpase activity and myosin heavy chain composition in rabbit muscle fibers. Histochemistry 86, 19-23
Crossref   Medline   1st Citation  

Termin, A, Staron, RS and Pette, D (1989) Myosin heavy chain isoforms in histochemically defined fiber types of rat muscle. Histochemistry 92, 453-57
Crossref   Medline   1st Citation  

Toyoshima, H and Hunter, T (1994) P27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to P21. Cell 78, 67-74
Crossref   Medline   1st Citation  

Verlinden, L, Verstuyf, A, Convents, R, Marcelis, S and Van Camp MBouillon, R (1998) Action of 1,25(Oh)2d3 on the cell cycle genes, cyclin D1, P21 and P27 in Mcf-7 cells. Mol Cell Endocrinol 142, 57-65
Crossref   Medline   1st Citation  

Walters, MR (1992) Newly identified actions of the vitamin D endocrine system. Endocr Rev 13, 719-64
Medline   1st Citation   2nd   3rd  

Yoshizawa, T, Handa, Y, Uematsu, Y, Takeda, S, Sekine, K and Yoshihara, Y (1997) Mice lacking the vitamin D receptor exhibit impaired bone formation, uterine hypoplasia and growth retardation after weaning. Nat Genet 16, 391-6
Crossref   Medline   1st Citation  

Zhang, X, Jiang, F, Li, P, Li, C, Ma, Q and Nicosia, SV (2005) Growth Suppression of ovarian cancer xenografts in nude mice by vitamin D analogue Eb1089. Clin Cancer Res 11, 323-8
Medline   1st Citation  


Received 1 November 2010/22 May 2011; accepted 26 January 2012

Published as Cell Biology International Immediate Publication 26 January 2012, doi:10.1042/CBI20100782


© The Author(s) Journal compilation © 2012 International Federation for Cell Biology


ISSN Print: 1065-6995
ISSN Electronic: 1095-8355
Published by Portland Press Limited on behalf of the International Federation for Cell Biology (IFCB)